APR 10, 2018 05:00 PM PDT

Gastric Cancer Screening Tool Using Serum Biomarkers Being Studied in South Korea

A new study focused on Gastric Cancer (GC) is evaluating a diagnostic screening tool utilizing a serum biomarker test panel which includes pepsinogen, H. pylori IgG, and Trefoil factor 3 (TFF3).  An additional outcome is to investigate the ideal timeframe intervals for performing GC screening endoscopies in South Korea. 

The observational study is still recruiting patients and aims to have their analysis completed by 2022.  The study is designed to survey newly diagnosed GC patients and a healthy control group.  There are multiple centers involved in the study and recruitment of patients.  As reported by the researchers in the clinical trial documentation, Korea has the highest incidence of GC; their focus is to help determine factors that will provide early diagnoses which have a more favorable prognosis.  There are multiple factors that increase the risk of gastric cancer including age, gender, genetics, family history, race, obesity, smoking, and H. pylori infection history.

There is an acknowledged precancerous cascade of changes resulting in GC.  GC traditionally begins with intestinal metaplasia which is recognized as a precancerous change.  The mucosa of the stomach lining yields initially to inflammation and is followed by damaging intestinal metaplasia (usually found as result of Helicobacter pylori infection).  Normal gastric mucosa is replaced by intestinal cells with partial or complete loss of the molecular features of gastric cells in the lesion location. 

The search for accurate, less invasive and expensive testing is an important and valid endeavor for all conditions, especially for cancer.  Current testing and screening includes serum pepsinogen (PG 1, PG II, and PG I/II ratio) which is reported to be a marker of mucosal atrophy; low values have consistently been found in GC patients.  Mucosal atrophy is often a strong indicator that a precancerous state is developing.  However, there are other possibilities for reduced levels of PG I or PG II.  This study looks to add TFF3 testing; TFF3 is a secretory protein expressed in gastrointestinal mucosa.  Recently published literature found with 73.4% sensitivity and 92% specificity that the optimal cutoff value of serum TFF3 was >8.9 ng/mL for GC diagnosis.  Another group recommended a TFF3 cutoff value of 3.6 ng/mL with 80.9% sensitivity and 81% specificity.  Of note, herein lies a challenge of determining appropriate reference ranges or cutoffs for diagnosis.  TFF3 also identified diffuse-type GC at 68.0% and 92.0% respectively. TFF3 is potentially a more stable marker than the serum PG test which had a 69.6% sensitivity and 68% specificity.  H. pylori serology, while not specifically outlined in the trial information, can be stratified by the degree of mucosal atrophy.  Reportedly the population in East Asia, Eastern Europe and parts of Central and South America have high seropositive H. pylori antibody rates so using this alone as a screening tool will have very low specificity for GC or precancerous change detection.  Including PG levels as a predictor combined with H. pylori seropositivity increases that specificity.  Combining pepsinogen, H. pylori IgG, and TFF3 values into a new diagnostic guide together could improve gastric cancer screening.  

Sources: NIH US. National Library of Medicine, Clinical and Experimental Medicine, Gut Liver Journal, Gastroenterology, Gastroenterology and Hepatology Journal, Disease Markers,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUN 01, 2018
Health & Medicine
JUN 01, 2018
Research Shows The Cause of Childhood Leukemia
Babies and young children need to be kept safe by the adults in their lives, however keeping them in a germ-free environment might not be the best idea. Ch...
JUN 27, 2018
Infographics
JUN 27, 2018
The Role of Biomarkers In Modern Medicine
A biomarker (short for biological marker) is a measurable indicator of some biological state or condition. The biomarker can be measured objectively and consistently. Biomarkers play signific...
JUL 17, 2018
Cancer
JUL 17, 2018
Immunotherapy Diversification: From CAR-T cells to CAR-NK cells
New advances have made it possible for immunotherapy researchers to use natural killer cells, which are our body's normal defense for cancerous cells, to target tumors....
JUL 25, 2018
Neuroscience
JUL 25, 2018
Can CT Scans Increase the Risk of Brain Cancer?
Medical imaging has gone from fuzzy X-rays that didn't show much, to real-time functional MRI scans in just a few decades. Being able to see inside the...
AUG 28, 2018
Drug Discovery
AUG 28, 2018
Combination Therapy for Advanced Melonoma
According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with a...
OCT 14, 2018
Immunology
OCT 14, 2018
The Stem of Cancer
Scientists reveal a pathway involved in cancer cell ability to act as stem cells...
Loading Comments...